• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Effient (prasugrel)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Effient (prasugrel)

  • Profile

Profile

Contact Information

Website: https://www.lillymedical.com/en-us/medical-information/cardiovascular/effient

Currently Enrolling Trials

    Show More

    General Information

    Effient (prasugrel) works by reducing the tendency of platelets, the blood particles responsible for clotting, from sticking or clumping together. Prasugrel blocks a specific receptor on the platelet surface, P2Y12 adenosine diphosphate (ADP), and prevents platelets from clumping, which can result in clogged arteries and may lead to heart attack.

    Effient is specifically indicated to reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows:

    • Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI)
    • Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.

    Efient is supplied as a 5 mg or 10 mg tablet for oral administration. The recommended initial dose of the drug is as a single 60 mg oral loading dose which may be continued at 10 mg orally once daily. Patients taking Effient should also take aspirin (75 mg to 325 mg) daily.
    Dosing in Low Weight Patients Patients weighing < 60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10 mg once daily maintenance dose. Consider lowering the maintenance dose to 5 mg in this population.

    Side Effects

    Adverse events associated with the use of Efient may include, but are not limited to, the following:

    • TIMI major or minor bleeding
    • Hypertension
    • Hypercholesterolemia/Hyperlipidemia
    • Headache
    • Back Pain
    • Dyspnea
    • Nausea
    • Dizziness

    Mechanism of Action

    Efient contains prasugrel, a thienopyridine class inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP receptor. Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.

    Clinical Trial Results

    The FDA approval of Efient was based on the results of TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel). This multicenter, international, randomized, double-blind, parallel-group study enrolled 13,608 subjects with ACS (UA, NSTEMI, or STEMI) who were to be managed with PCI. The subjects were randomized to receive Effient (60 mg loading dose followed by 10 mg once daily) or clopidogrel (300 mg loading dose followed by 75 mg once daily), with administration and follow-up for a minimum of 6 months (actual median 14.5 months). Patients also received aspirin (75 mg to 325 mg once daily). The primary outcome measure was the composite of cardiovascular death, nonfatal MI, or nonfatal stroke in the UA/NSTEMI population. Success in this group allowed analysis of the same endpoint in the overall ACS and STEMI populations. Efient produced a statistically significant reduction in this primary endpoint of 19% when compared to Plavix (p=0.0004). This was observed as early as three days into treatment. In a subgroup of subjects with diabetes, prasugrel reduced each of the endpoints by 21% in subjects with STEMI (p=0.02) and 18% in subjects with unstable angina (p=0.002), compared to Plavix. In addition, prasugrel resulted in a 34% decline in urgent target vessel revascularization (p<0.001) and a 42% reduction in heart attack with subsequent death from cardiovascular causes (p=0.02). Prasugrel treated subjects also had a statistically significant increase in non-CABG (coronary artery bypass grafting) major bleeding compared to Plavix-treated subjects (2.4% vs. 1.8%, p=0.03). Fatal bleeding was statistically more frequent among prasugrel-treated than clopidogrel-treated subjects (0.4% vs. 0.1%, p=0.002). Overall, prasugrel showed a higher clinical benefit over Plavix, with a significant 13% reduction in overall events (12.2 vs. 13.9, p=0.004).

    Approval Date: 2009-07-01
    Company Name: Eli Lilly
    Back to Listings

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing